A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 27, 2017

Primary Completion Date

August 20, 2019

Study Completion Date

April 21, 2020

Conditions
Pyoderma Gangrenosum
Interventions
DRUG

adalimumab

Study drug will be administered subcutaneously.

Trial Locations (20)

7558505

Yamaguchi University Hospital /ID# 164562, Ube-shi

467-8602

Nagoya City University Hospital /ID# 164510, Nagoya

279-0021

Juntendo University Urayasu Hospital /ID# 164422, Urayasu Shi

814-0180

Fukuoka University Hospital /ID# 164416, Fukuoka

960-1295

Fukushima Medical University Hospital /ID# 164358, Fukushima

371-8511

Gunma University Hospital /ID# 164464, Maebashi

078-8510

Asahikawa Medical University Hospital /ID# 164589, Asahikawa-shi

227-0043

Showa University Fujigaoka Hospital /ID# 164406, Yokohama

514-8507

Mie University Hospital /ID# 164389, Tsu

980-8574

Tohoku University Hospital /ID# 164360, Sendai

〒390-8621

Shinshu University Hospital /ID# 164852, Matsumoto-shi

852-8501

Nagasaki University Hospital /ID# 167604, Nagasaki

903-0215

University of the Ryukyus Hospital /ID# 164981, Nakagami-gun

431-3192

Hamamatsu University Hospital /ID# 165890, Hamamatsu

770-8503

Tokushima University Hospital /ID# 164359, Tokushima

173-8605

Teikyo University Hospital /ID# 165665, Itabashi-ku

160-0023

Tokyo Medical University Hospital /ID# 165810, Shinjuku-ku

160-8582

Keio University Hospital /ID# 165680, Shinjuku-ku

573-1191

Kansai Medical Univ Hosp /ID# 165802, Hirakata-shi, Osaka

060-8648

Hokkaido University Hospital /ID# 164419, Sapporo

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY